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Abstract
Background: In periaqueductal grey (PAG) matter, cross-talk between the Mu-opioid receptor (MOR) and the glutamate N-
methyl-D-Aspartate receptor (NMDAR)-CaMKII pathway supports the development of analgesic tolerance to morphine. In
neurons, histidine triad nucleotide binding protein 1 (HINT1) connects the regulators of G protein signaling RGSZ1 and
RGSZ2 to the C terminus of the MOR. In response to morphine, this HINT1-RGSZ complex binds PKCc, and afterwards, the
interplay between PKCc, Src and Gz/Gi proteins leads to sustained potentiation of NMDAR-mediated glutamate responses.
Methodology/Principal Findings: Following an intracerebroventricular (icv) injection of 10 nmol morphine, Akt was
recruited to the synaptosomal membrane and activated by Thr308 and Ser473 phosphorylation. The Akt activation was
immediately transferred to neural Nitric Oxide Synthase (nNOS) Ser1417. Afterwards, nitric oxide (NO)-released zinc ions
recruited PKCc to the MOR to promote the Src-mediated phosphorylation of the Tyr1325 NMDAR2A subunit. This action
increased NMDAR calcium flux and CaMKII was activated in a calcium-calmodulin dependent manner. CaMKII then acted on
nNOS Ser847 to produce a sustained reduction in NO levels. The activation of the Akt-nNOS pathway was also reduced by
the binding of these proteins to the MOR-HINT1 complex where they remained inactive. Tolerance to acute morphine
developed as a result of phosphorylation of MOR cytosolic residues, uncoupling from the regulated G proteins which are
transferred to RGSZ2 proteins. The diminished effect of morphine was prevented by LNNA, an inhibitor of nNOS function,
and naltrindole, a delta-opioid receptor antagonist that also inhibits Akt.
Conclusions/Significance: Analysis of the regulatory phosphorylation of the proteins included in the study indicated that
morphine produces a transient activation of the Akt/PKB-nNOS pathway. This activation occurs upstream of PKCc and Src
mediated potentiation of NMDAR activity, ultimately leading to morphine tolerance. In summary, the Akt-nNOS pathway
acts as a primer for morphine-triggered events which leads to the sustained potentiation of the NMDAR-CaMKII pathway
and MOR inhibition.
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Introduction
The coexistence of ligand-regulated metabotropic and iono-
tropic receptors in the postsynapse raises the possibility of mutual
interactions triggered by the relative abundance of their
presynaptic mediators. Among ligand-gated ionotropic receptors,
glutamate N-methyl-D-Aspartate receptors (NMDARs) have
received particular attention because of their crucial roles in
excitatory synaptic transmission, plasticity, and neurodegeneration
[1]. NMDARs are composed of NR1, NR2 (A, B, C, and D) and
NR3 (A and B) subunits. They form a tetramer consisting of a pair
of NR1 subunits associated with at least one type of NR2/3
subunits [2]. The NMDAR controls a cation channel that is highly
permeable to Ca
2+. In general, G-protein coupled receptors
(GPCRs) regulate NMDAR activity through the action of non-
receptor tyrosine kinases including Src, Fyn and serine/threonine
kinases such as protein kinase C (PKC) [3]. Non-receptor tyrosine
kinases phosphorylate specific tyrosine residues in the cytosolic tail
of NR2 and, potentially, NR3 subunits [4], producing an increase
in the permeation of Ca
2+ ions towards the cytosolic side of the
postsynapse. PKC is essential to the potentiation of NMDARs.
This kinase enhances the activity of Src [5]; PKC promotes the
regulatory phosphorylation of serine and threonine residues in the
cytosolic regions of NR1 and NR2 subunits [6–8]; it directly elicits
the potentiation of NMDAR responses by removing the inhibitory
binding of Ca-Calmodulin (Ca
2+-CaM) on NR1 subunits [9].
The Mu-opioid receptor (MOR) is a well-characterized GPCR
in terms of its regulation by NMDARs. MOR signaling can be
modulated by the NMDAR/NO cascade [10,11], and the
development of morphine-induced desensitization is a conse-
quence of the activity of glutamate NMDARs [12,13]. The
interaction between these receptors is bidirectional, and MOR
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in glutamate-activated NMDAR currents [14,15]. Thus, the
attenuation of opioid efficacy that is observed in certain states of
persistent pain is caused by an anomalous increase in NMDAR
function [16]. This cross-regulation also provides the molecular
basis for understanding the clinical efficacy of NMDAR
antagonists in opioid-induced tolerance [17,18]. The supraspinal
analgesic effects of intracerebroventricular (icv)-injected opioids
are mediated through their binding to MORs located in the
periaqueductal grey matter (PAG) of the midbrain [19,20]. The
rostral ventromedial medulla (RVM) which includes the nucleus
raphe magnus and the laterally adjacent reticular formation is the
major relay of midbrain PAG neurons that project down to the
substantia gelatinosa in the dorsal horn of the spinal cord. There,
these projections reduce the intensity of the ascending nociceptive
signals [21,22]. This midbrain system also participates in the
antinociceptive effects of systemic morphine. Thus, lesions in the
medulla or spinal cord that affect descending projections from the
RVM as well as opioid antagonists delivered into the RVM
diminish the effects of systemic morphine [21]. In humans, icv
morphinotherapy is a very effective treatment for chronic
intractable pain of cancerous origin [23]. Also, deep brain
stimulation targeting PAG has been used to treat intractable pain
for over 50 years. The analgesia produced by electrical stimulation
of PAG is mediated by the release of endogenous opioids acting at
MORs [24], and it has been successful in alleviating phantom limb
pain, post-herpetic neuralgia, anesthesia dolorosa, brachial plexus
injury and diverse neuropathies [25,26].
Therefore, the PAG is of particular physiological relevance in
the nociceptive modulating network that operates both at a
supraspinal level and also through dorsal horn interneurons. In
recent studies, it has been shown that the MOR carries a signaling
complex in its C terminus that is integrated by HINT1 and RGSZ
proteins [27,28]. In response to morphine, NMDAR-nNOS
generated zinc recruits PKCc to the HINT1-RGSZ complex.
Together with Src and MOR-activated Gi and Gz proteins, the
complex integrates the molecular machinery that carries signals
from MOR to the NMDAR [11,29]. Cross-regulation between
MORs and NMDARs creates a negative feedback loop. As a
result, NMDAR inhibits MOR signaling [30]. Although pharma-
cological approaches have identified a series of signaling proteins
involved in this process, little is known concerning whether they
operate in the same regulatory machinery, and also the
chronological order in which they are activated. There is a
possibility, however, that MOR may regulate other events
upstream of PKC and Src activation as well.
The phosphoinositide 3-kinase (PI3K) cascade has been
associated with MOR desensitization [31]. Akt, a 57 kDa
serine/threonine protein kinase, also known as protein kinase B
or Rac, mediates the effects of PI3K [32]. MOR activates Akt via
Gi/o and PI3K [33,34] as well as regulating Akt expression in
neural cells [35,36]. Akt contains a pleckstrin homology (PH)
domain at its N-terminus followed by a kinase domain and a
carboxy terminal regulatory domain. The PH domain, which
contains approximately 120 amino acids, can be found in a wide
range of proteins involved in intracellular signaling. This domain
can bind phosphatidylinositol lipids within biological membranes,
such as phosphatidylinositol (3,4,5)-triphosphate (PIP3) and
phosphatidylinositol (4,5) biphosphate (PIP2). The nNOS pathway
has also been linked to the development of morphine tolerance
[37]. Interestingly, NMDAR signaling elicits nNOS activation via
the PI3K-Akt pathway [38].
The PAG is of relevance in the treatment of chronic pain in
humans and it is essential in the analgesic effects produced by icv
and systemic opioids. Thus, we wanted to analyze in this neural
structure the connection between morphine-activated MORs and
the Akt-nNOS pathway. Because the HINT1 protein is required
for morphine to recruit PKCc to the MOR environment, we
evaluated in HINT1 (2/2) mice this possibility but with Akt and
nNOS. We also evaluated the inhibition of Akt and nNOS enzyme
activities on the morphine-induced transient associations observed
between MORs and signaling proteins as well as in the
development of analgesic tolerance to morphine.
Materials and Methods
Animals, intracerebroventricular injection and evaluation
of antinociception
Male albino CD-1 mice weighing 22–25 g were used through-
out the study. The mice were housed and used in accordance with
the guidelines of the European Community for the Care and Use
of Laboratory Animals (Council Directive 86/609/EEC). This
research has been approved by the Bioethics Committee of the
‘‘Consejo Superior de Investigaciones Cientı ´ficas (CSIC)’’. The
animals were housed at 22uC under a 12 h light/dark cycle (lights
on from 8 a.m. to 8 p.m.). Food and water were provided ad
libitum. Response to nociceptive stimuli was determined with a
warm water (52uC) tail-flick test. Baseline latencies ranged from
1.5 to 2.2 seconds. These latencies were not significantly affected
by naltrindole (Tocris 0740) or the nNOS inhibitor L-NG-
Nitroarginine (LNNA, Tocris 0664). A cut-off time of ten seconds
was implemented to minimize the risk of tissue damage.
Antinociception was expressed as a percentage of the maximum
possible effect (MPE), where MPE =100 x (test latency (s) -
baseline latency (s))/(cut-off time 10 s-baseline latency (s)). Groups
of eight to ten mice were lightly anesthetized with ether and
injected with a 10 nmol dose (4 mL total volume) of morphine
sulfate (Merck, Darmstadt, Germany) into the lateral ventricle.
Following the injection, antinociception was assessed at several
time points.
The tail-flick analgesic test applies a thermal noxious stimulus to
promote flicking of the mouse’s tail, and opioids increase the time
elapsed between application of the stimulus and the flick. This
response comprises a spinal reflex which is under facilitator drive
by the brain stem nociceptive modulating network [39]. After icv
administration of opioids, the MORs in the ventral region of PAG
[40] play an important role in the supraspinal pathways that
modulate spinal nociceptive processing [41]. Thus, icv morphine
modulates descending serotoninergic and adrenergic systems and
inhibits responses to nociceptive stimuli, including nociceptive
withdrawal reflexes that are organized segmentally, such as the
hind limb withdrawal and tail flick reflexes [42]. The icv doses of
the opioid required to produce these effects affect regions with
poor density of MORs such as the ventricle walls, the PAG which
is responsible of MOR-mediated analgesia, and to a minor extent
the floor of the 4
th ventricle without reaching the spinal level [43].
Our molecular studies that analyzed the interaction of signaling
proteins with the MOR were performed in HINT1 (+/+) and
HINT1 (2/2) mice (128SvJ strain) [44]. Breeding pairs of
homozygous wild type (WT) and knockout (KO) mice, generously
supplied by Drs. I.B. Weinstein and J.B. Wang, were obtained
from hybrid mutant mice, originally created on a 129SvJ-C57BL/
6 background, by backcrossing mice from the 129 strain for several
generations. Thus, 96% of the genetic background of the mice
used in the present study comes from the 129 strain. Animals used
in this study were 8 to12 weeks-old adult male mice. The genotype
was confirmed with PCR analysis of DNA extracted from tail
biopsies. The absence of the HINT1 protein results in a phenotype
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the animals’ mood [45].
Production of acute tolerance and the interval required
to recover the analgesic response
The animals received an icv priming dose of either 3 nmol or
10 nmol morphine in the right lateral ventricle. A 3 nmol dose
produced 40–50% of the maximum analgesic effect. A 10 nmol
dose, on the other hand, produced 70–80% of the maximum
analgesic effect. Controls were injected only with the opioid
priming dose, whereas the experimental group received either
naltrindole or LNNA prior to the morphine priming dose. Mice
from the control and experimental groups were divided into sub-
groups of eight mice each and icv-injected with increasing test
doses of morphine 24 h after the priming dose. The effect of
morphine was evaluated at 30 min post-injection; allowing time
for the compound to reach its peak analgesic effect. Development
of acute tolerance was ascertained by constructing an analgesic
Figure 1. Control of Akt-nNOS pathway by the action of morphine on MORs. 10 nmol morphine was icv-injected into CD1 mice. At various
intervals post-injection, the mice were sacrificed and the PAG structures were collected. The presence of Akt and nNOS in the PAG synaptosomal
membrane was determined. Also, the association of these proteins with the MOR was evaluated. At each time point studied, the PAG structures from
four to six mice were pooled. MOR proteins were immunoprecipitated and the co-precipitated Akt and nNOS were evaluated. Immunosignals
(average optical density of the pixels within the object area/mm
2; Quantity One Software, BioRad) were expressed as the change relative to the
control animals (attributed an arbitrary value of 1). Each data point represents the mean of three assays performed on PAG samples obtained from
independent groups of mice. Data are presented as the area below the curve (Sigmaplot v11), the upper curve indicates the +SEM. For comparison,
we have superimposed the control levels of the pair of curves being compared. Upper panel: The effect of morphine on the presence of Akt in the
synaptosomal PAG membrane and the MOR environment. The presence of activating Thr308 and Ser473 phosphorylations in the membrane-
associated Akt. Insets: Representative western blots of these data. An absence of phosphorylation in Akt recruited to the MOR was shown but not
plotted. MOR-rcted stands for MOR-recruited. Lower panel: A similar study of nNOS was carried out. Enzyme levels associated with PAG synaptosomal
membranes and MORs were determined. The presence of Akt-activating Ser1417 phosphorylation and CaMKII-inactivating Ser847 phosphorylation
were also determined in membrane-associated nNOS. Insets: Representative nNOS western blots are shown. nNOS that was recruited to the MOR
environment lacked Ser1417 and Ser847 phosphorylation.
doi:10.1371/journal.pone.0011278.g001
Figure 2. HINT1 protein binds to a series of signaling proteins at the C terminus. PAG synaptosomal membranes prepared from HINT1
(2/2) 129 SvJ mice were used to immunoprecipitate MORs and the association of the signaling proteins with MORs was studied. Signals
corresponding to the MOR in HINT1 (2/2) and (+/+) mice were paired and co-precipitated proteins were directly compared. These assays were
repeated twice on samples obtained from different mice. The results were consistent across replicates.
doi:10.1371/journal.pone.0011278.g002
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analgesic effect of the 10 nmol priming dose had dissipated as
evidenced by the restoration of baseline latencies in the tail-flick
test. Data are expressed as the mean 6 SEM from groups of eight
mice.
Co-immunoprecipitation of signaling proteins
To compare the analgesic effects with molecular events, we
examined the PAG, a discrete neural structure. Synaptosomal
membranes were obtained from groups of six to ten mice that were
sacrificed by decapitation at various intervals following an icv
injection of 10 nmol morphine. PAG tissue was collected and
homogenized in 10 volumes of 25 mM Tris-HCl (pH=7.4) and
0.32 M sucrose. The homogenized mixture was supplemented
with a phosphatase inhibitor mixture (Sigma, P2850), protein
kinase inhibitor H89 (Sigma, B1427) and a protease inhibitor
cocktail (Sigma, P8340). The homogenate was centrifuged at
1000g for 10 min to remove the nuclear fraction. Then, the
synaptosomal fraction was isolated [46,47]. The final pellet was
diluted in Tris buffer and supplemented with a mixture of protease
inhibitors (0.2 mM phenylmethylsulphonyl fluoride, 2 mg/mL
leupeptin, and 0.5 mg/mL aprotinin) before it was aliquoted and
frozen at 280uC.
The membranes (0.5 g) were sonicated (two cycles of 5 s each)
in a 1 mL mixture containing 50 mM Tris-HCl (pH=7.7),
50 mM NaCl, 1% Nonidet P-40, 50 mL of protease and
phosphatase inhibitor mixtures, as well as H89. Affinity-purified
IgGs against the second extracellular loop of the MOR and the C-
terminus of RGSZ2 proteins were labeled with biotin (Pierce
#21217 & 21339). The target proteins were then immunoprecip-
itated from solubilized membranes as described previously [46,48].
At the end of the procedure, proteins in the soluble fraction were
concentrated in centrifugal filter devices (Amicon Microcon YM-
10 #42407, Millipore) and solubilized by heating the samples at
100uC for 10 min in 2x Laemmli buffer containing mercaptoeth-
anol. Once the samples cooled, the proteins were resolved by SDS-
PAGE using 10–16% gels.
Analysis of MOR phosphorylation
Because unidentified proteins might co-precipitate with the
MORs and interfere with phosphoserine analysis (clone 1C8,
Calbiochem, 525281), existing protein interactions were disrupted
under denaturing conditions prior to performing immunoprecip-
itation. PAG synaptosomal membranes prepared in presence of
phosphatase inhibitor mixture (Sigma, P2850), protein kinase
inhibitor H89 (Sigma, B1427) and a protease inhibitor cocktail
(Sigma, P8340) were heated in 40 mM Tris–HCl, 1% SDS buffer,
2-mercaptoethanol for 10 min at 100uC. The mixture was cooled
to room temperature and the SDS concentration was reduced by
adding octylthioglucoside to a final concentration of 0.65%. MOR
was immunoprecipitated with biotinylated IgGs and after
removing the IgGs the absence of accompanying proteins was
verified by silver staining. The MOR detection procedure was
continued as described above.
Detection of signaling proteins in mouse brain:
electrophoresis and immunoblotting
Western blots were probed with affinity-purified IgG antibodies
directed against: murine MOR (1:1000 dilution) [46]; Gai2, Gaz
(1:2000) [49]; RGS17(Z2) [46,50]; NMDAR1 (1:1000, Abcam
ab1880); NMDAR1 phospho-Ser890 (Cell Signaling #3381);
NMDAR2A (1:1000, ab14596); NMDAR2A phospho-Y1325
(1:300, ab16646); CaMKII (1:3000; BD Transduction labs
611292); CaMKII phospho-Thr286 (1:2000; Cell Signaling
3361); PKCc (1:1000; Abcam ab4145). Akt (1:1000; Cell Signaling
4691); Akt phospho-Thr308 (1:1000; Cell Signaling 2965); Akt
phosphor-Ser473 (1:1000; Cell Signaling 4060); nNOS (1:1000;
Santa Cruz SC-1025); nNOS phospho-Ser1417 (2 mg/mL;
Abcam ab5583); nNOS phospho-Ser847 (1 mg/mL; Abcam
ab16650) and Actin (1:3000; Stressgen, CSA-400). Anti-histidine
triad nucleotide binding protein 1 (HINT1) antibody was raised in
rabbits (Immunostep, Spain) against the peptide sequence
GYRMVVNEGADGGG (aa 93–106).
The 1C8 mouse monoclonal antibody (IgM) was used to detect
phosphoserines (Calbiochem #525281). The antibodies were
diluted in TBS + 0.05% Tween 20 (TTBS) and incubated with
the PVDF membranes for 24 h at 6uC. Primary antibodies were
detected using corresponding secondary antibodies conjugated to
horseradish peroxidase (diluted 1:10,000 in TTBS). Antibody
binding was visualized with an Immobilon Western Chemilumi-
nescent HRP substrate (Millipore #WBKLS0100). Chemilumi-
nescence was recorded with a ChemiImager IS-5500 (Alpha
Innotech, San Leandro, California). Assays were performed in
replicates of two or three on samples obtained from independent
groups of mice. The results were consistent across all replicates.
Results
Regulation of Akt-nNOS pathway by morphine
To analyze the effect of morphine on Akt activity, an acute
10 nmol dose was injected icv into mice. This dose has been
shown to induce MOR-mediated analgesic desensitization [51].
Animals were sacrificed at various intervals post-injection, and the
synaptosomal fraction of PAG structures was obtained for
immunodetection and co-precipitation studies. During the first
15 min following morphine administration, the amount of
membrane-associated Akt increased approximately 1.7-fold. This
increase was followed by a decrease at 30 min, and after 90 min,
the levels had dropped to below baseline. Hours later, Akt
expression returned to control levels. The Akt pool was activated
by the phosphorylation of Thr308 and Ser473 residues (Fig. 1,
upper panel). Interestingly, 30 min to 3 h post-morphine, Akt was
Figure 3. The Influence of Akt and nNOS in the production of supraspinal analgesia and changes in MOR-associated transduction
as a result of morphine exposure. Upper panel: CD1 mice were icv-injected with increasing doses of morphine and antinociception was
monitored with the warm water (52uC) tail-flick test. Data correspond to the peak-effect interval at 30 min post-injection and are presented as dose-
response curves. Individual values represent the mean 6 SEM from a group of eight mice. The development of morphine-induced single-dose
tolerance and its pharmacological rescue were studied 24 h after receiving a priming dose of 3 nmol or 10 nmol morphine. The analgesic effect of
increasing test doses of morphine was then evaluated at 30 min post-injection. The nNOS inhibitor, LNNA (7 nmol), and the mixed Delta-opioid
receptor antagonist/Akt inhibitor, naltrindole (1 nmol), were icv-injected prior to the 10 nmol morphine priming dose. LNNA was injected 30 min
before the priming dose, whereas naltrindole was administered 90 min before the priming dose. Lower panel: LNNA and naltrindole were
administered to the CD1 mice prior to the 10 nmol morphine priming dose. Mice were sacrificed at the indicated time points. For each time point
studied, PAG structures from four to six mice were pooled. The MOR was immunoprecipitated and serine phosphorylation was evaluated (see
Materials and Methods). Co-precipitation of Gai2 subunits with MORs and RGSZ2 proteins was also evaluated. Further data and details are shown in
Fig. 1.
doi:10.1371/journal.pone.0011278.g003
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localization was the inverse to the amount of Akt found in the
membrane. Importantly, Akt proteins recruited to MOR lacked
phosphorylation on both the Thr308 and Ser473 residues.
There was a transient increase in nNOS in the synaptosomal
membrane 45 min to 3 h post-morphine. Afterwards, nNOS
returned to levels observed prior to the opioid challenge. These
changes corresponded with a decrease in the association of nNOS
with the MOR during this particular interval (Fig. 1, lower panel).
Similar to Akt, membrane-associated nNOS had regulatory
phosphorylation at Ser1417 and Ser847, but phosphorylation
was almost undetectable for MOR-associated nNOS. Membrane-
associated nNOS was phosphorylated by Akt on Ser1417. This
phosphorylation activates and enhances the production of nitric
oxide (NO) in the presence of Ca
2+-CaM [38]. This activation,
however, is transitory and is followed by an inactivating
phosphorylation at Ser847, a CaMKII site [52]. Naloxone, an
opioid antagonist, inhibits the effects of morphine on Akt-nNOS
activation, indicating the involvement of MORs (not shown).
The HINT1 protein drives the recruitment of Akt and
nNOS to the MOR
In neural cells, the C terminus of the MOR interacts with a
signaling complex formed by HINT1 and RGS proteins members
of the RGS-Rz subfamily. The HINT1 protein binds directly to
sequences in the MOR cytosolic C tail and also in the N terminus
of the RGSZ1 and RGSZ2 proteins [27,53]. Morphine-induced
MOR activation recruits PKC, primarily PKCc, to this complex,
where it is activated by diacylglycerol (DAG). DAG is generated by
the action of Gbc dimers on PLCb [11]. In the present study, we
have evaluated whether the observed association between MORs,
Akt and nNOS depends on the presence of the HINT1-RGSZ
complex. MORs immunoprecipitated from PAG synaptosomes
isolated from HINT1 (2/2) 129SvJ mice were associated with
regulated G proteins, but not PKCc, Akt or nNOS (Fig. 2). PKCc
binds directly to the HINT1-RGSZ complex through NMDAR-
nNOS generated zinc ions [11].
MOR enhances NMDAR function via Akt-nNOS
The icv administration of morphine produces a dose-dependent
antinociceptive effect in the tail-flick test that peaks 30 min after
the injection. In CD1 mice, the administration of a 10 nmol opioid
dose elicits a profound decrease in response to successive doses of
morphine [46]. This tolerance was present when the dose-response
curve of morphine was assessed 24 h after the animals had
received the 10 nmol morphine priming dose. The ED50 (nmol
icv morphine/mouse) was 4.84 for control mice (95% confidence
limits 3.63–6.43). Prior studies have shown that tolerance to
morphine can be attenuated by nNOS inhibitors and the delta-
opioid receptor antagonist, naltrindole [37]. Naltrindole, however,
has recently been described as a cell permeable inhibitor of the Akt
signaling pathway [54]. When mice were pre-treated with 10 nmol
of morphine, they showed a profound tolerance with an ED50
.10 nmol/mouse. If mice were injected 30 min before the
priming dose with 7 nmol of the competitive nNOS inhibitor
LNNA, or 90 min before the priming dose with 1 nmol
naltrindole, a delta-opioid receptor antagonist [55] and Akt
inhibitor [54], morphine tolerance did not develop (Fig. 3, upper
panel).
A single dose of 10 nmol morphine does not promote
internalization of neural MORs [46]. Instead, the desensitizing
effects of morphine are mediated by the phosphorylation of serine
residues on the cytosolic receptor sequences as well as by the
reduction of some of the regulated G proteins. During its analgesic
time-course, a 10 nmol morphine dose brings about the
progressive transfer of MOR-regulated Ga subunits towards the
control of RGS proteins (e.g., the RGSZ2) [46,50]. This
impairment of MORs to regulate their transduction results in
morphine tolerance. In agreement with previous reports, ex vivo
assays showed the following after a morphine challenge: the
presence of MORs in the membrane surface remained constant,
morphine increased the recruitment of PKCc at the MOR, which
became phosphorylated, and a gradual loss of regulated G proteins
was increasingly associated with RGSZ2 proteins [11,46].
Administration of LNNA or naltrindole before morphine abol-
ished the development of analgesic tolerance, prevented the
recruitment of PKCc at the MOR, inhibited phosphorylation of
the opioid receptor and interfered with the transfer of G proteins
from MOR control toward RGSZ2 control (Fig. 3, lower panel).
Regulatory loop MOR-Akt-nNOS-NMDAR-CaMKII-MOR
One of the main targets of GPCR-regulated Src is the
cytoplasmic tail of the NR2A and NR2B subunits [4,56]. The
10 nmol morphine dose promoted PKC-mediated phosphoryla-
tion of NMDAR1 Ser890 and Src-mediated phosphorylation of
NMDAR2A Tyr1325. Both phosphorylations were previously
found to enhance NMDAR function [29,37]. Indeed, these
changes are associated with the activating Thr286 autopho-
sphorylation of CaMKII. Again, administration of LNNA or
naltrindole before morphine prevented the phosphorylation of
NMDAR subunits and the activation of CaMKII as well (Fig. 4).
Notably, naltrindole reduced phosphorylation of Akt on Thr308
and Ser473. Therefore, independent of its antagonist activity at
the delta-opioid receptor, naltrindole may act as a cell permeable
inhibitor of Akt [54].
In neuronal cells, the glutamate NMDAR is important for both
the control and desensitization of the MOR [12,13,30]. Mor-
phine-activated MOR enhances NMDAR-mediated glutamate
responses [14], bringing about the activation of CaMKII [15].
CaMKII, in turn, inhibits MOR signaling [30]. Fig. 5 shows the
chronology of a series of morphine-triggered events that
participate in the regulation of MOR signaling and development
of analgesic tolerance. Considering that time 0 is the moment of
morphine icv-injection, the earliest event observed was Akt
activation, which was immediately followed by the activating
phosphorylation of nNOS. Shortly afterwards, PKCc was
recruited to the MOR, NR2A was phosphorylated and the
presence of Gai2 decreased at the MOR. These events coincided
with a decrease in the activation of Akt via pThr308, the
appearance of active pThr286 CaMKII and subsequent reduction
of nNOS activity via an increase of pSer847 and dephosphory-
lation of pSer1417. CaMKII activation was also followed by the
Figure 4. The Influence of the Akt-nNOS pathway on morphine-induced NMDAR potentiation. Upper panel: The influence of 10 nmol icv
morphine on NMDAR activity was evaluated. The levels of NMDAR1 and of NMDAR2A subunits and activating phosphorylations at NR1 Ser890 (PKC
site) and NR2A Tyr1325 (Src site) were monitored in the CD1 PAG synaptosomal membranes during the post-morphine intervals indicated. The
presence of the Thr286 autophosphorylation of NMDAR-activated CaMKII was also determined. Administration of LNNA or naltrindole before
morphine greatly reduced NR1, NR2A and CaMKII phosphorylation. Lower panel: Naltrindole decreased Akt/PKB activating phosphorylation. Please
see Materials and Methods for further details.
doi:10.1371/journal.pone.0011278.g004
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MOR toward the RGSZ2 protein. For longer intervals (6 h and
24 h post-morphine), most of these changes were still present,
although the magnitude was reduced: Akt recovered some
activating phosphorylation, PKCc was still observed at MORs
and the levels of pTyr1325 NMDAR2 and of pThr286 CaMKII
decreased almost to the control level. The phosphorylation of the
MOR, however, was still present, as was the association between
Ga subunits and RGSZ2 proteins.
Discussion
Our results indicate that in PAG morphine binding to MORs
elicits sustained potentiation of NMDAR function through the
activation of the Akt/PKB-nNOS pathway upstream of PKCc
and Src. Akt activation was observed a few minutes after morphine
administration and was rapidly transmitted to the nNOS. This
indicates that the MOR is coupled to the production of NO via the
Akt-nNOS pathway. Notably, early Akt-nNOS activation was
immediately followed by a decrease in its strength prior to the
30 min interval, the time when the peak analgesic effect of
morphine was reached. A series of regulatory mechanisms, such as
the recruitment of Akt to the MOR, were triggered to control
neuronal NO levels. Moreover, transient Akt-activating phosphor-
ylation of nNOS Ser1417 [38] was followed by a robust increase in
CaMKII-mediated inactivating phosphorylation of nNOS Ser847
[57]. As observed for Akt, the morphine-activated MOR also
recruited inactive nNOS to reduce the stamina of the Akt-nNOS
pathway. Therefore, morphine triggers a series of mechanisms that
efficiently control the production of NO, which could help prevent
cellular damage caused by NO overproduction. In fact, morphine
exerts a protective effect in peroxynitrite-induced apoptosis of
neural cells, a mechanism involving G proteins and PI3K [58].
Morphine also protects primary rat astrocytes from glutamate-
induced death [59].
In a previous study, we reported that morphine promotes the
recruitment of PKCc to the HINT1-RGSZ complex at the MOR
carboxy-terminus [11]. The MOR–PKCc association involves the
cysteine rich domains in the regulatory C1 region of PKCc, NO,
free zinc ions, HINT1 and RGSZ proteins. The binding of
inactive Akt and nNOS to the MOR also involves the HINT1
protein. However, it appears to be independent of zinc ions and
may require a third partner protein. The precise protein
interactions between HINT1 and Akt or nNOS are presently
being explored.
A number of GPCRs regulate NMDAR activity through the
action of kinases such as Src and PKC [3,37]. PKC is involved in
MOR-generated signals that promote sustained potentiation of
NMDAR-mediated glutamate responses [15]. Through its recruit-
ment to the MOR, PKCc is allocated close to potential substrates
where DAG promotes its activation. The presence of zinc ions and
DAG in the regulatory domain of PKC extends the activation
period of this kinase [11,48]. This characteristic contributes to the
long-term NMDAR-mediated desensitization of MORs that is
observed even after the antinociceptive effects of a desensitizing
dose of morphine have disappeared. Thus, the MOR increases
calcium ion permeation through the NMDAR via PKCc, Src
tyrosine kinase and Gi proteins [29]. Afterwards, CaMKII is
activated and inhibits MOR signaling [30]. Inhibition of nNOS by
LNNA prevents morphine tolerance [37,60], sustained potentia-
tion of NMDAR function and subsequent CaMKII activation.
Notably, naltrindole reduced Akt activation, suggesting that it can
act as a cell permeable Akt inhibitor in vivo [54]. Another
possibility is that naltrindole could preserve morphine analgesia by
Figure 5. Chronology of morphine-triggered changes in MOR-
regulated signaling proteins. 10 nmol morphine was icv-injected
into the CD1 mice at time 0. The data, the mean of three assays
performed on PAG samples obtained from independent groups of mice,
are presented as the area below the curve (Sigmaplot v11) and the
upper curve indicates +SEM. In instances where a pair of curves is
plotted together, the control levels have been superimposed. Details
are provided in the legends for Figs 1, 3 & 4.
doi:10.1371/journal.pone.0011278.g005
Akt in MOR-NMDAR Cross-Talk
PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e11278acting as an antagonist to delta-opioid receptors [37]. Naltrindole,
however, was useful in demonstrating the role of Akt as an initiator
of morphine tolerance via NMDAR potentiation.
The sequence of these morphine-triggered events is described in
Fig. 6. The productive binding of morphine to MORs induces the
release of free Gbc dimers from activated Gao/iGTP subunits (1).
Agonist-freed Gbc dimers remain attached to the membrane
through lipids that are covalently-bound to the N-terminus of the
Gc subunit (2). Binding to heterodimeric PI3K translocates this
lipid kinase to the membrane (3) in contact with its substrates [61].
Membrane-associated PIP2 is converted into PIP3 by PI3K (4)
and recruits the PH domain of Akt to the membrane (5) where it is
phosphorylated by Phosphoinositide Dependent protein Kinase 1
(PDK1), which also has a PH domain at its C-terminus. PDK1 is
recruited to the membrane by PI3K-generated PIP3 (5) where it
phosphorylates and activates AGC kinases, such as PKC and Akt,
through phosphorylation of Akt Thr308 (6). Akt activation is
dependent on phosphorylation of two sites: PDK1 phosphoryla-
tion of Thr308 in the kinase activation loop and PDK2
phosphorylation of Ser473 at the C-terminus (6). Ser473
phosphorylation is dependent on PI3K. However, the identity of
the PDK2 acting on Thr308 is still controversial. Phosphorylation
of both Ser473 and Thr308 residues contribute to Akt activation
[32]. Akt induces a rapid and transient phosphorylation of nNOS
Figure 6. A diagram summarizing the proposed connection between MOR and NMDAR and the role of the Akt-nNOS pathway in
cross-regulation. See Discussion for details.
doi:10.1371/journal.pone.0011278.g006
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zinc ions from metallothioneins (9) and recruitment of PKCc to
the HINT1-RGSZ complex at the MOR C-terminus (10). In the
postsynapse, the regulation of nNOS is dependent on the balance
between activating and inactivating phosphorylation. Akt activates
nNOS, whereas CaMKII inactivates it [38,57,62,63].
Physiological stimulation brings about the release of glutamate
and zinc from synaptic vesicles. Zinc ions enter postsynaptic
neurons through specific ionotropic receptors such as NMDA
receptors, AMPA receptors and voltage-gated calcium channels
[64]. When nNOS-generated NO operates on AMPA receptors
(11) and potentiates NMDAR function (12), the levels of
permeated calcium and zinc increase. Ca
2+-CaM then increases
and activates CaMKII (13) that, in turn, acts on nNOS Ser847 to
reduce Ca
2+-CaM binding and NO production (14). The rapid
and transient MOR-dependent Akt-mediated nNOS serine1417
phosphorylation followed by sustained CaMKII phosphorylation
of serine847 has also been observed for NMDAR-activated PI3K-
Akt [38]. As a result of this regulation, NO production is only
transiently activated. During intervals of diminished NO produc-
tion due to the loss of Akt activity and the action of CaMKII on
nNOS, the zinc ions required for PKCc to bind to the MOR-
HINT1 must come from another source. NMDAR-permeated
zinc takes control over the recruitment of PKCc to the MOR, (15)
where the action of morphine on PLCb (16) promotes PKCc
activation (17). Antagonism of NMDARs elicits decreased PKCc
recruitment to postsynaptic sites [65]. The concerted action of
PKC and Src (18) result in sustained NMDAR potentiation (19).
This MOR to NMDAR activating loop is downregulated by
CaMKII-mediated negative feedback to inhibit MOR (20).
CaMKII, a Ca
2+-CaM-activated protein kinase that is highly
abundant in the CNS, has emerged as a critical factor in the
NMDAR to MOR section of the regulatory loop. There is
convincing evidence that supports the role of CaMKII in the
development of morphine tolerance: CaMKII activity is increased
in brain areas of animals with morphine tolerance [66,67] and
administration of KN62 and KN93, specific CaMKII inhibitors,
significantly reduces morphine tolerance in mice and rats [68–70].
Furthermore, antisense oligonucleotides that specifically decrease
the expression of CaMKII attenuate morphine tolerance and
dependence [69]. Activated CaMKII produces a prolonged
reduction of nNOS activity [52], and reduces MOR signaling
[30]. PKC activity also participates in AMPA-mediated potenti-
ation of NMDAR function [71,72] and is critical for the
development of morphine tolerance. Soon after PKCc translocates
to the MOR, activated Ga subunits are progressively transferred
under the control of certain RGS proteins by a PKC-dependent
mechanism [46,48]. These processes occur before repeated
morphine administration leads to internalization and recycling of
the neural MOR, a process mediated by GRKs and b-arrestins
[46].
A growing body of evidence indicates that MORs and
NMDARs coexist in the postsynapse, explaining the relationship
between opioids and glutamatergic NMDARs. These receptors
are co-expressed in areas of the CNS, such as in PAG neurons
[37]. Both MOR and NMDAR are modulated by spinophilin
(neurabin II) [73,74], a dendrite spine marker [75]. Moreover, at
the ultrastructural level, both receptors show co-localization [76],
suggesting that MOR and NMDAR could physically interact in
the manner described for GPCRs such as D1, mGlu5a and the
NR1 subunit of the NMDAR [77–79]. In fact, results generated by
several studies indicate that most experimental approaches that
interfere with the development of morphine analgesic tolerance
can be assembled into a common regulatory machinery, which
connects MOR and NMDAR function [37]. Our analyses of the
on-off regulating phosphorylation of signaling proteins indicate
that they work in a concatenated manner, with every step
depending on the completion of the preceding step. This
regulation integrates the positive effects of PI3K, Akt, nNOS,
PKC, Src, NMDAR and CaMKII on MOR inhibition. The
efficacy of the described treatments in preventing and rescuing
morphine analgesia from tolerance can be explained by linking
early events with those responsible for sustained NMDAR
potentiation and subsequent CaMKII action on MORs. Upon
inhibition of these early processes (e.g., Akt or nNOS), the
subsequent steps responsible for NMDAR sustained potentiation
and MOR tolerance do not occur. If PKC is inhibited or the
NMDAR is blocked, then the early steps fail to transmit signals for
activation and no tolerance develops. Similarly, the inhibition of
CaMKII prevents MOR phosphorylation and reduces AMPAR
function [80]. As a result, a less pronounced morphine tolerance
develops [30]. In summary, early activation of Akt and nNOS
initiates the PKCc-Src pathway responsible for sustained poten-
tiation of NMDAR-CaMKII function. This sustained potentiation
results in MOR inhibition and produces an analgesic tolerance to
morphine.
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